Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer

How does the FDA handle unprecedented decisions? What’s it like to go on “Good Morning America”? And does the world need a “New” GlaxoSmithKline?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we sift through the week’s news, with a major update from Eli Lilly in Alzheimer’s disease and new details on the inner workings of the FDA. Then, STAT’s Matthew Herper joins us to discuss how GlaxoSmithKline ended up in a self-preservation struggle. Finally, STAT’s Nicholas St. Fleur calls in to talk about the alarming rise of colorectal cancer deaths among young men and his decision to get on an on-camera colonoscopy for a reporting project.

For more on what we cover, here’s the news from Lilly; here’s more on the FDA; here’s the latest on GSK; here’s the colorectal cancer story; here’s the colonoscopy feature; here’s the 2021 STAT Breakthrough Science Summit; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].